Trial reportEuropean journal of nuclear medicine and molecular imaging2012
The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure.
Trial report in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Cardiac Contractility Modulation and Arrhythmic Burden in Heart Failure: Mechanistic Rationale, Clinical Evidence, and Future Perspectives.Journal of cardiovascular development and disease · 2026Review
- Cardiac contractility modulation in heart failure management: unraveling molecular mechanisms to improve patient selection in heart failure management.Heart failure reviews · 2026Review
- Cardiac Contractility Modulation (CCM) Therapy in Contemporary Heart Failure Care: Mechanisms, Evidence, Patient Selection, and Emerging Directions.Journal of clinical medicine · 2026Review
- Cardiac contractility modulation in patients with heart failure - A review of the literature.Heart failure reviews · 2024Review
- Streamlining Randomized Clinical Trials for Device Therapies in Heart Failure: Bayesian Borrowing of External Data.Journal of the American Heart Association · 2024Article
- Molecular effects of cardiac contractility modulation in patients with heart failure of ischemic aetiology uncovered by transcriptome analysis.Frontiers in cardiovascular medicine · 2024Article
- A Multistep Approach to Deal With Advanced Heart Failure: A Case Report on the Positive Effect of Cardiac Contractility Modulation Therapy on Pulmonary Pressure Measured by CardioMEMS.Frontiers in cardiovascular medicine · 2022Article
- Cardiac contractility modulation ameliorates myocardial metabolic remodeling in a rabbit model of chronic heart failure through activation of AMPK and PPAR-α pathway.Open medicine (Warsaw, Poland) · 2022Article
- Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond.European journal of heart failure · 2019Review
- Inappropriate Defibrillator Shocks due to Mechanical Inference from an Investigational Device.Case reports in cardiology · 2019Article
- [Cardiac contractility modulation for treatment of chronic heart failure].Herzschrittmachertherapie & Elektrophysiologie · 2018Review
- [Cardiac contractility modulation].Der Internist · 2018Review
- Cardiac contractility modulation: a novel approach for the treatment of heart failure.Heart failure reviews · 2016Review
- Cardiac Contractility Modulation for Heart Failure: Current and Future Directions.Journal of the Society for Cardiovascular Angiography & InterventionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCardiac contractility modulation (CCM) is a device-based therapy that involves delivery of nonexcitatory electrical signals resulting in improved ventricular function and a reversal of maladaptive cardiac fetal gene programmes. Our aim was to evaluate whether acute application of CCM leads to an increase in myocardial oxygen consumption (MVO(2)) in patients with chronic heart failure using (11)C-acetate positron emission tomography (PET).
methodsWe prospectively enrolled 21 patients with severe heart failure. (11)C-acetate PET was performed before and after activation of the CCM device. In 12 patients an additional stress study with dobutamine was performed.
resultsUnder resting conditions, the values of myocardial blood flow (MBF), MVO(2) and work metabolic index (WMI, reflecting myocardial efficiency) with the CCM device activated did not differ significantly from the values with the device deactivated. MBF was 0.81 ± 0.18 ml min(-1) g(-1) with the device off and 0.80 ± 0.15 ml min(-1) g(-1) with the device on (p = 0.818), MVO(2) was 6.81 ± 1.69 ml/min/100 g with the device off and 7.15 ± 1.62 ml/min/100 g with the device on (p = 0.241) and WMI was 4.94 ± 1.14 mmHg ml/m(2) with the device off and 5.21 ± 1.36 mmHg ml/m(2) with the device on (p = 0.344). Under dobutamine stress, the values of MBF, MVO(2) and WMI with the CCM device activated did not differ from the values with the device deactivated, but were significantly increased compared with the values obtained under resting conditions.
conclusionThese results indicate that CCM does not induce increased MVO(2), even under stress conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.